COVER STORY Vol. 39 Issue No. 11

India - A Cure For Pharma Outsourcing Woes?

CDMOs: Unsung Hero of Pharmaceutical Value Chain

Pharmaceutical companies are making a transition to asset-light models, focusing on core competencies. This is where India’s contract development and manufacturing organisations (CDMOs) step in, offering a potential remedy. Hence, both domestic as well as international companies are partnering with CDMOs for drug development, regulatory support and risk-sharing to expedite project timelines and ensure cost-effective manufacturing at scale while maintaining stringent quality standards. The report highlights the role of the CDMO companies and their future prospects 

Special Report

Infrastructure Sector Is It Reaching For The Skies?

Infrastructure Stocks Soar amidst Buying Spree

With the upcoming Lok Sabha elections looming, many of us may be feeling the urge to invest in infrastructure stocks, hoping for a favourable impact on investments if a strong political mandate ensues. Mandar Wagh delves into the government’s emphasis on infrastructural development, future growth triggers and the critical factor of fundamentals that must be taken into consideration before investing 

All That Shines is Gold & Silver 

Performance of Gold, Silver and Nifty 50

Precious metals gold and silver hold a special place when it comes to the investment journey of Indians. They help diversify investment risks and provide a hedge against market volatility, making them an essential component of a well-rounded investment strategy. Vaishnavi Chauhan explores the impact of precious metals on your portfolio. 

MF - Cover Story

When Is The Right Time To Sell Mutual Funds?

As investors, the most challenging task isn’t just selecting the right fund but also knowing when to sell them judiciously. This report highlights the various factors that investors must consider to be able to make maximum profit out of their funds or at times exit before it is too late. 

MF - Special Report

All You Wanted To Know About SIP

Is rupee cost averaging effective across all market phases, including uptrends, consolidations and downtrends? You probably might not have observed its performance in each phase or may have exited investments upon seeing negative returns. Rakesh Deshmukh takes a closer look at the scenario.